Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Beta: 1.3719 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688443 Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
43 GF Score
Price ¥25.03
! 4 Warning Signs
View Full Analysis

What is Chongqing Genrix Biopharmaceutical Co Beta?

Chongqing Genrix Biopharmaceutical Co SHSE:688443 +0.81% 43 Beta is 1.3719 as of Jul. 21, 2026. GuruFocus rates SHSE:688443 with a GF Score™ of 43/100. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-21), Chongqing Genrix Biopharmaceutical Co's Beta is 1.3719.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Chongqing Genrix Biopharmaceutical Co Beta Related Terms


Chongqing Genrix Biopharmaceutical Co Beta Historical Data

* Premium members only.

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chongqing Genrix Biopharmaceutical Co Beta Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SHSE:688443 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Beta distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Beta falls into.


SHSE:688443
43GF Score
Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chongqing Genrix Biopharmaceutical Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.3719 mean?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a Beta of 1.3719 as of Jul. 21, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chongqing Genrix Biopharmaceutical Co and its competitors.
Is Chongqing Genrix Biopharmaceutical Co's Beta too high?
Chongqing Genrix Biopharmaceutical Co's current Beta is 1.3719. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's Beta compare to VRTX and REGN?
Chongqing Genrix Biopharmaceutical Co's Beta of 1.3719 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chongqing Genrix Biopharmaceutical Co and its competitors. Chongqing Genrix Biopharmaceutical Co's current Beta is 1.3719. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a current Beta of 1.3719. The current Beta is 1.3719. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current Beta is 1.3719 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chongqing Genrix Biopharmaceutical Co Business Description

Address No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan District, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
43GF Score

Get the complete analysis for SHSE:688443

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥25.03
Price